KDR and acute myeloid leukemia: Side effects were as well known for refractory/relapsed AML and were identical to those previously mentioned in other Linifanib trials as adverse drug effects following VEGFR inhibition, namely fatigue, diarrhea, skin toxicities, proteinuria, and hypertension [96–98].